Immunosuppressive therapies in myasthenia gravis

References

• Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006; 63:60–72.
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006; 68:1–12.
   PubMedGoogle Scholar
• Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol. 2006; 120:260–271.
   PubMed Web of Science ®Google Scholar
• Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: Effect of immunosuppressive treatment. Immunology. 2005; 116:134–141.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Papaioannou A. In whom and how to prevent glucocorticoid-induced osteoporosis. Best Pract Res Clin Rheumatol. 2006; 19:1039–1064.
   Google Scholar
• Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol. 2003; 39:1073–1077.
   PubMed Web of Science ®Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998; 50:1778–1783 The Myasthenia Gravis Study Group.
   PubMed Web of Science ®Google Scholar
• Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc. 1998; 30:2167–2170.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006; 108:390–399.
   PubMed Web of Science ®Google Scholar
• Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. New Engl J Med. 1987; 316:719–724.
   PubMed Web of Science ®Google Scholar
• Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci. 1993; 681:539–551.
   PubMed Web of Science ®Google Scholar
• Ponseti JM, Azem Z, Fort JM, Lopez-Cano M, Vilalonga R, Buera M, Cervera C, Armengol M. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology. 2005; 64:1641–1643.
   PubMed Web of Science ®Google Scholar
• Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002; 25:111–114.
   PubMed Web of Science ®Google Scholar
• Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry. 2005; 76:448–450 the Japanese FK.
   PubMed Web of Science ®Google Scholar
• Kamakura K, Kanzaki M, Ogawa G, Mochizuki H, Kaida KI, Motoyoshi K. Tacrolimus as a treatment for severe myasthenia gravis. J Neuroimmunol. 2006; 178:231–232.
   Google Scholar
• Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis—a randomized pilot study. Eur Neurol. 2005; 53:146–150.
   PubMed Web of Science ®Google Scholar
• de Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002; 26:31–36.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “Rebooting” with high-dose cyclophosphamide. Ann Neurol. 2003; 53:29–34.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Myasthenia Gravis and Related Disorders: 11th International Conference 2008; 1132:305–314.
   Google Scholar
• Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation. 2003; 75 Suppl.: 37S–42S.
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006; 34:284–291.
   PubMed Web of Science ®Google Scholar
• Hehir MK, Burns TM, Alpers JP, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody positive myasthenia gravis: Outcomes in 102 patients. Muscle & Nerve. 2010 in press.
   Google Scholar
• Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, Melms A, Nicolle MW, Solomons N, Richman DP. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008; 71:400–406.
   PubMed Web of Science ®Google Scholar
• The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008; 71:394–399.
   Google Scholar
• Sanders DB, Siddiqi ZA Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Myasthenia Gravis and Related Disorders: 11th International Conference 2008; 1132:249–253.
   Google Scholar
• Phan C, Sanders DB, Siddiqi ZA. Mycophenolate mofetil in myasthenia gravis: The unanswered question. Exp Opin Pharmacother. 2008; 9:2545–2551.
   PubMed Web of Science ®Google Scholar
• Gold R, Schneider-Gold C. Current and future standards in the treatment of myasthenia gravis. Neurotherapeutics. 2008; 5:535–541.
   PubMed Web of Science ®Google Scholar
• Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediat. 2003; 143:674–677.
   PubMed Web of Science ®Google Scholar
• Tandan R, Potter C, Bradshaw DY. Pilot trial of rituximab in myasthenia gravis. Neurology. 2008; 70:A301.
   Google Scholar
• Gardner R, Pestronk A, Al-Lozi MT. Intractable myasthenia gravis responding to rituximab treatment. Neurology. 2008; 70:A301.
   Google Scholar
• Kerkeni S, Marotte H, Miossec P. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve. 2008; 38:1343–1345.
   Google Scholar
• Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol. 2008; 201:90–94.
   Google Scholar
• Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of musk antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006; 33:575–580.
   PubMed Web of Science ®Google Scholar
• Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry. 2007; 78:771.
   PubMed Web of Science ®Google Scholar
• Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2009; in press.
   Google Scholar
• Stugen JP. B-cell targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol. 2008; 204:1–12.
   Google Scholar
• Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 20081–17.
   Google Scholar
• Benatar M, Kaminski H. Practice parameter: The medical treatment of ocular myasthenia (an evidence-based review). Neurology. 2007; 68:2144–2149.
   PubMedGoogle Scholar
• Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007; CD005224:1–31.
   Google Scholar
• Sanders DB, Massey JM, Juel VC. MuSK-antibody MG: Response to various treatments in 32 patients. Ann NY Acad Sci. 2008; 1132:382.
   Google Scholar
• Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: Questions from the clinic. J Neuroimmunol. 2008; 201–202:85–89.
   PubMed Web of Science ®Google Scholar
• Evoli A, Tonali PA, Padua L, Lo Monaco M, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126:2304–2311.
   PubMed Web of Science ®Google Scholar
• Lavrnic D, Losen M, de Baets M, Hajdukovic LJ, Stojanovic V, Trikic R, Djukic P, Apostolski S. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005; 76:1099–1102.
   PubMed Web of Science ®Google Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis. Recommendations for clinical research standards. Neurology. 2000; 55:16–23.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Brenner T, Fuchs S. Development of novel therapies for MG: Studies in animal models. Autoimmunity. 2010; 43 5: 446–460.
   Google Scholar
• Lagoumintzis G, Zismopoulou P, Kordas G, Lazaridis K, Poulas K, Tzartos SJ. Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis. Autoimmunity. 2010; 43 5: 436–445.
   Google Scholar
• Tuzun E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-[gamma] benefit from etanercept treatment. J Autoimmun. 2005; 24:261–268.
   PubMed Web of Science ®Google Scholar
• Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004; 63:2390–2392.
   PubMed Web of Science ®Google Scholar
• Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve. 2009; 39:866–870.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. Anti-c5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007; 179:8562–8567.
   PubMed Web of Science ®Google Scholar
• Monfardini C, Milani M, Ostlie N, Wang W, Karachunski PI, Okita DK, Lindstrom J, Conti-Fine BM. Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes. J Neuroimmunol. 2002; 123:123–134.
   Google Scholar
• Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol. 2004; 152:112–120.
   PubMed Web of Science ®Google Scholar
• Feferman T, Aricha R, Maiti PK, Clairac G, Cuvelier M, Berrih-Aknin S, Fuchs S, Souroujon MC. DNA microarray analysis: New drug targets for myasthenia gravis. J Neuroimmunol. 2006; 178:123.
   Google Scholar
• Araga S, Xu L, Nakashima K, Vallain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J. 2000; 14:185–196.
   PubMed Web of Science ®Google Scholar
• Galin FS, Chrisman CL, Cook JRJr, Xu L, Jackson PL, Noerager BD, Weathington NM, Blalock JE. Possible therapeutic vaccines for canine myasthenia gravis: Implications for human disease and associated fatigue. Brain Behav Immun. 2007; 21:323–331.
   PubMed Web of Science ®Google Scholar